期刊文献+

小剂量安体舒通对慢性肾衰竭病人心功能的影响

Effect of low dosage of antisterone on cardiac function in patients with chronic renal failure
下载PDF
导出
摘要 目的:观察安体舒通对慢性肾衰竭(CRF)并充血性心力衰竭(CHF)病人心功能的影响及安全性。方法:63例CKI合并NYHA心功能Ⅲl~Ⅳ级CHF住院患者,随机分为治疗组和对照组。对照组常规给以速尿、硝普钠、硝酸异山梨酯治疗;治疗组在常规治疗基础上加用安体舒通40mg/d,连续用药12个月。用药前后分别进行心功能、心脏多普勒超声检查,心率(HR)测定,定期测定血K+、Na+、Cl-、BUN、Cr,并做心电图及血压监测。结果:治疗组的疗效显著优于对照组(P<0.05),再住院及病死率较对照组显著减少(P<0.05);治疗组的心功能及心脏多普勒超声指标、HR均较对照组明显改善(P<0.05),血BUN、Cr浓度较对照组有显著改善(P<0.05),无严重副作用。结论:长期使用小剂量安体舒通治疗慢性肾衰竭并CHF安全有效。 Objective: To observe the safety and the effects of antisterone on cardiac function in patients with chronic renal failure complicated with congestive heart failure. Methods: Sixty-three in-patents of chronic renal failure were enrolled, with cardiac function NYHA Ⅲ~Ⅳ grade. They were randomly divided into treatment group and control group. The patient of control group were given routinetherapy. The antisterone 40mg/d were given for twelve months continuously based on the routine treatment in patients of treatment group. After the treating, the cardiac function was compared with that before treating. Heart rate, ion concentrates (K^+, Na^+, Cl^-), renal function, electrocardiogram and blood pressure were monitored. Results: In treatment group, thetherapentic effect, cardiac function, heart rate and renal function were greatly improved (P〈0.05), the rehospitalization rate and mortality were significantly decreased (P〈0.05) compared with control group. Conclusion: It is safe and effective to treating CRF patients complicated with chronic heart failure with low dosage of antisterone for a long time.
出处 《心血管康复医学杂志》 CAS 2007年第1期73-76,共4页 Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词 肾功能衰竭 慢性 安体舒通 心力衰竭 充血性 Renal failure, chronic Antisterone Heart failure, congestive
  • 相关文献

参考文献7

  • 1Al-Ahmand A,Sarnak MJ,Salem DN,et al.Cause and management of herat failure in patients with chronic renal disease[J].Semin Nephol,2001,21(1):3-12.
  • 2Amannk Trallak.Cardiovascular changes in chronic renal failure-pathogenesis and therapy[J].Clin Nephrol,2002,58(suppl):62-72.
  • 3Tyralla K,Amann K.Morphollgy of the heart and arteries in renal failure[J].Kidney Int,2003,84(suppl):80-83.
  • 4McMahon EG.Recent studies with eplerenonl,a novel seleceive aldost erone receptor antagonist[J].Curr opin pharmacol,2001,1(2):190-196.
  • 5程远植.醛固酮拮抗剂螺内酯在慢性心力衰竭治疗中的作用机制和应用进展[J].中华心血管病杂志,2003,31(1):69-71. 被引量:111
  • 6Zannad F,Alla AF,Dousset B,et al.Limitation of excessive ectracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure:insights from the randomized aldactone evaluation study(RALES)[J].Rales Investigators,2001,2:2700.
  • 7Banersachs J,Fraccarono D,Ertl G,et al.Striking increase of natriuresis by low-dose spironolactone in cogestive heart failare only in combination with ACE in Hibition[J].Circulation,2000,102(19):2325-2328.

共引文献110

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部